Working group for technical specifications for blood pressure measuring devices
Recommendations and technical specifications for a blood pressure measuring device in low resource settings were developed in WHO Affordable Technology BP Device at Low Resource (2005). Since then, countries are in different stages of phasing out mercury blood pressure device due to the toxicity of mercury and observer bias, by replacing automated devices. Practical issues are now raised in LMIC countries, in terms of criteria choosing automated BP device in different settings, accuracy, cuff size, calibration and validation protocols, and training.
There was also an urgent need to update the WHO guidance and develop specifications to reflect the latest technology improvement, standards and build consensus to shape the global market with quality medical device.
Given this context, the Management of Noncommunicable Diseases team (MND) at WHO HQ in collaboration with Innovation, Access and Use (IAU) team at WHO HQ, has initiated the work to update the WHO guidance and develop the technical specifications for blood pressure measuring devices.
The goals and objectives of the working group are presented below:
- discuss and form consensus on the key recommendations and evidence;
- finalize working document;
- plan on implementation, training and capacity support to LMICs.
- to assess the evidence on and agree on thresholds for pharmacological management of hypertensions
- to assess the evidence for, and agree on, appropriate pharmacological management of hypertension
In order to enhance its management of Conflicts of Interest as well as strengthen public trust and transparency in connection with WHO meetings involving the provision of technical/normative advice, the names and brief biographies of individuals (“Published Information”) being considered for participation in such meetings are disclosed for public notice and comment.
The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.
The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments and perceptions brought to the knowledge of WHO through this process are an integral component of WHO’s conflict of interest assessment policy and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert with no attribution to the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.
The participation of an expert in a WHO meeting does not imply that they are endorsed or recommended by the World Health Organization nor does it create a binding relationship between the expert and WHO.
The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publicly in accordance with WHO practice.